NO984565L - Influensavirus replikert i pattedyrcellekultur og vaksinefremstilling - Google Patents

Influensavirus replikert i pattedyrcellekultur og vaksinefremstilling

Info

Publication number
NO984565L
NO984565L NO984565A NO984565A NO984565L NO 984565 L NO984565 L NO 984565L NO 984565 A NO984565 A NO 984565A NO 984565 A NO984565 A NO 984565A NO 984565 L NO984565 L NO 984565L
Authority
NO
Norway
Prior art keywords
cell culture
mammalian cell
influenza viruses
vaccine production
viruses replicated
Prior art date
Application number
NO984565A
Other languages
English (en)
Other versions
NO984565D0 (no
Inventor
Robert G Webster
Nicolai V Kaverin
Original Assignee
St Jude Childrens Res Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by St Jude Childrens Res Hospital filed Critical St Jude Childrens Res Hospital
Publication of NO984565D0 publication Critical patent/NO984565D0/no
Publication of NO984565L publication Critical patent/NO984565L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16151—Methods of production or purification of viral material
    • C12N2760/16152—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
NO984565A 1996-04-05 1998-09-30 Influensavirus replikert i pattedyrcellekultur og vaksinefremstilling NO984565L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US62838496A 1996-04-05 1996-04-05
US08/664,783 US5824536A (en) 1994-08-23 1996-06-17 Influenza virus replicated in mammalian cell culture and vaccine production
PCT/US1997/005518 WO1997038094A1 (en) 1996-04-05 1997-04-02 Influenza virus replicated in mammalian cell culture and vaccine production

Publications (2)

Publication Number Publication Date
NO984565D0 NO984565D0 (no) 1998-09-30
NO984565L true NO984565L (no) 1998-12-03

Family

ID=27090697

Family Applications (1)

Application Number Title Priority Date Filing Date
NO984565A NO984565L (no) 1996-04-05 1998-09-30 Influensavirus replikert i pattedyrcellekultur og vaksinefremstilling

Country Status (8)

Country Link
US (2) US5824536A (no)
EP (1) EP0895535A4 (no)
AU (1) AU2722997A (no)
CA (1) CA2250716A1 (no)
DE (1) DE895535T1 (no)
ES (1) ES2139553T1 (no)
NO (1) NO984565L (no)
WO (1) WO1997038094A1 (no)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19612967A1 (de) * 1996-04-01 1997-10-02 Behringwerke Ag Verfahren zur Vermehrung von Influenzaviren in Zellkultur, sowie die durch das Verfahren erhältlichen Influenzaviren
NZ512980A (en) * 1998-12-17 2003-07-25 Aventis Pasteur Multivalent immunogenic composition containing RSV subunit composition and influenza virus preparation
IL136232A0 (en) * 2000-05-18 2001-05-20 Bar Ilan University Res Author Measurements of enzymatic activity in a single, individual cell in population
DE10144906B4 (de) 2001-09-12 2013-11-28 Novartis Vaccines And Diagnostics Gmbh Verfahren zur großtechnischen Herstellung von Impfstoffen
EP1438385A1 (en) * 2001-10-25 2004-07-21 Bar-Ilan University Interactive transparent individual cells biochip processor
US6951752B2 (en) * 2001-12-10 2005-10-04 Bexter Healthcare S.A. Method for large scale production of virus antigen
US6830917B2 (en) 2001-12-10 2004-12-14 Baxter Healthcare S.A. Method of isolation and purification of trypsin from pronase protease and use thereof
AU2002239151A1 (en) * 2002-03-08 2003-09-22 Crucell Holland B.V. Use of recombinant trypsin for vaccine production
DK1499348T3 (en) 2002-04-26 2015-01-05 Medimmune Llc PROCEDURE FOR PREPARING INFECTIOUS INFLUENZA B-VIRA IN CELL CULTURE
US7465456B2 (en) * 2002-04-26 2008-12-16 Medimmune, Llc Multi plasmid system for the production of influenza virus
EP2481819A1 (en) 2003-02-25 2012-08-01 MedImmune Vaccines, Inc. Cross flow filtration in the production of stabilized influenza vaccine compositions
US20060110406A1 (en) 2003-02-25 2006-05-25 Medimmune Vaccines, Inc. Refrigerator-temperature stable influenza vaccine compositions
IL154677A0 (en) * 2003-02-27 2003-09-17 Univ Bar Ilan A method and apparatus for manipulating an individual cell
RU2330885C2 (ru) * 2003-06-18 2008-08-10 Федеральное государственное учреждение науки "Государственный научный центр вирусологии и биотехнологии "Вектор" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека (ФГУ ГНЦ ВБ "Вектор" Роспотребнадзора) Способ получения живой культуральной вакцины против вируса гриппа
WO2004110484A1 (en) * 2003-06-18 2004-12-23 Gosudarstvenny Nauchny Tsentr Virusologii I Biotekhnologii 'vektor' Method for producing a live tissue-cultural vaccine against influenza virus
CA2503774C (en) * 2003-06-20 2007-09-25 Microbix Biosystems Inc. Improvements in virus production
EP1654347B1 (en) * 2003-06-26 2014-06-04 Seng Enterprises Limited Improved materials for constructing cell-chips, cell-chip covers, cell-chip coats, processed cell-chips and uses thereof
US9200245B2 (en) 2003-06-26 2015-12-01 Seng Enterprises Ltd. Multiwell plate
US8597597B2 (en) * 2003-06-26 2013-12-03 Seng Enterprises Ltd. Picoliter well holding device and method of making the same
US7888110B2 (en) * 2003-06-26 2011-02-15 Seng Enterprises Ltd. Pico liter well holding device and method of making the same
WO2005008626A1 (en) * 2003-07-11 2005-01-27 University Of North Carolina At Chapel Hill Methods and systems for controlling a computer using a video image and for combining the video image with a computer desktop
US20050064524A1 (en) * 2003-08-11 2005-03-24 Mordechai Deutsch Population of cells utilizable for substance detection and methods and devices using same
US7037707B2 (en) * 2003-09-04 2006-05-02 St. Jude Children's Research Hospital Method for generating influenza viruses and vaccines
CA2551489C (en) 2003-12-23 2013-09-03 Gregory Duke Multi plasmid system for the production of influenza virus
WO2005074893A1 (en) * 2004-02-03 2005-08-18 Chemagis Ltd. Stable amorphous forms of montelukast sodium
US20080063251A1 (en) * 2004-07-07 2008-03-13 Mordechai Deutsch Method and Device for Identifying an Image of a Well in an Image of a Well-Bearing
US7403647B2 (en) * 2004-09-13 2008-07-22 Seng Enterprises Ltd. Method for identifying an image of a well in an image of a well-bearing component
US20080009051A1 (en) * 2004-08-25 2008-01-10 Seng Enterprises Ltd. Method and Device for Isolating Cells
ATE489965T1 (de) 2004-09-09 2010-12-15 Novartis Vaccines & Diagnostic Verminderung von potentiellen iatrogenen risiken in verbindung mit influenza impfstoffen
FR2878860A1 (fr) * 2004-12-08 2006-06-09 Vivalis Sa Lignees de cellules souches humaines derivees de cellules es et utilisations pour la production de vaccins et de proteines recombinantes
DK2368975T3 (en) 2004-12-23 2015-01-05 Medimmune Llc Non-tumorigenic MDCK cell line for the propagation of viruses
DE602005023534D1 (de) 2005-01-25 2010-10-21 Seng Entpr Ltd Mikrofluidische vorrichtung zur untersuchung zellen
US11865172B2 (en) 2005-04-21 2024-01-09 University Of Florida Research Foundation, Inc. Materials and methods for respiratory disease control in canines
US7959929B2 (en) 2005-04-21 2011-06-14 University Of Florida Research Foundation, Inc. Materials and methods for respiratory disease control in canines
EP1917352A4 (en) * 2005-06-21 2009-03-25 Medimmune Vaccines Inc METHODS AND COMPOSITIONS FOR EXPRESSING HETEROLOGOUS PROTEASE
US7790434B2 (en) * 2005-06-21 2010-09-07 Medimmune, Llc Methods and compositions for expressing negative-sense viral RNA in canine cells
DE102005034043B4 (de) * 2005-07-18 2019-12-12 Südzucker Aktiengesellschaft Mannheim/Ochsenfurt Gemisch, enthaltend L-Carnitin und Trehalulose, sowie Produkt enthaltend das Gemisch
US20070111309A1 (en) * 2005-10-04 2007-05-17 Daelli Marcelo G Vero cell line adapted to grow in suspension
US20070141555A1 (en) * 2005-10-11 2007-06-21 Mordechai Deutsch Current damper for the study of cells
ES2525518T3 (es) 2005-11-01 2014-12-26 Novartis Vaccines And Diagnostics Gmbh Vacunas virales derivadas de células con niveles reducidos de ADN celular residual
US8288120B2 (en) * 2005-11-03 2012-10-16 Seng Enterprises Ltd. Method for studying floating, living cells
US11707520B2 (en) 2005-11-03 2023-07-25 Seqirus UK Limited Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
CA2628152C (en) 2005-11-04 2016-02-02 Novartis Vaccines And Diagnostics S.R.L. Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
JP2009514844A (ja) * 2005-11-04 2009-04-09 ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル スプリットインフルエンザワクチン用のアジュバントとしての遊離水相界面活性剤を含むエマルション
DK2016194T3 (en) 2006-04-19 2015-06-15 Medimmune Llc METHODS AND COMPOSITIONS FOR EXPRESSION OF VIRAL NEGATIVE SENSE RNA IN DOG CELLS
EP4585610A3 (en) * 2006-09-11 2025-09-24 Seqirus UK Limited Making influenza virus vaccines without using eggs
EP2615167A1 (en) 2006-09-15 2013-07-17 MedImmune, LLC Method for eliminating DNA contaminants from viral preparations
WO2008036285A1 (en) * 2006-09-18 2008-03-27 Energex Systems, Inc. Method of treating viral infections with ultraviolet light
EP1911836A1 (en) 2006-10-12 2008-04-16 AVIR Green Hills Biotechnology Trading GmbH Medium supplement for virus production
US20110053248A1 (en) * 2006-10-23 2011-03-03 Medimmune, Llc Serum-Free Virus Propagation Platform For A Virus Vaccine Candidate
PT2121011E (pt) * 2006-12-06 2014-07-31 Novartis Ag Vacinas compreendendo um antigénio a partir de quatro estirpes do vírus da gripe
JP2010512748A (ja) * 2006-12-15 2010-04-30 シェーリング−プラウ・リミテッド インフルエンザウイルスを培養物中で複製するための方法
CA2766173A1 (en) * 2006-12-15 2008-06-26 Schering-Plough Ltd. Method for replicating influenza virus in culture
US20090060889A1 (en) * 2007-03-12 2009-03-05 Von Hofe Eric Ii-RNAi involved Ii suppression in cancer immunotherapy
EP2144594A4 (en) * 2007-04-13 2012-12-05 Academia Sinica ALPHA-GALACTOSYL CERAMIDE ANALOGUES AND THEIR USE IN IMMUNOTHERAPIES
US7758867B2 (en) * 2007-06-15 2010-07-20 Biotrion Co., Ltd. Attenuated influenza virus and a live vaccine comprising the same
EP2674486A1 (en) * 2007-06-18 2013-12-18 MedImmune, LLC Influenza B viruses having alterations in the hemaglutinin polypeptide
US9145540B1 (en) 2007-11-15 2015-09-29 Seng Enterprises Ltd. Device for the study of living cells
EP2237887A2 (en) 2007-12-26 2010-10-13 Seng Enterprises Ltd. Device for the study of living cells
RU2377295C1 (ru) * 2008-06-11 2009-12-27 Федеральное государственное учреждение науки "Государственный научный центр вирусологии и биотехнологии "Вектор" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека (ФГУН ГНЦ ВБ "Вектор" Роспотребнадзора) Питательная среда для культивирования клеток млекопитающих
US7928077B2 (en) * 2008-07-11 2011-04-19 Academia Sinica Alpha-galactosyl ceramide analogs and their use as immunotherapies
US20110150926A1 (en) * 2008-08-01 2011-06-23 Mohammed Alsharifi Influenza vaccines
US8785173B2 (en) 2008-09-24 2014-07-22 Medimmune, Llc Methods for purification of viruses
EP2344634A4 (en) * 2008-09-24 2012-08-29 Medimmune Llc METHODS OF CELL CULTURE, AND PROPAGATION AND PURIFICATION OF VIRUSES
EP3173097A3 (en) 2009-02-10 2017-07-12 Seqirus UK Limited Influenza vaccines with reduced amounts of squalene
US20120058145A1 (en) * 2009-05-08 2012-03-08 Bruno Rene Andre Method for producing virus from cell culture involving homogenization
WO2010144797A2 (en) 2009-06-12 2010-12-16 Vaccine Technologies, Incorporated Influenza vaccines with enhanced immunogenicity and uses thereof
CA2803282C (en) 2009-07-06 2018-05-01 David E. Anderson Methods for preparing vesicles and formulations produced therefrom
JP5854559B2 (ja) 2009-07-06 2016-02-09 ヴァリエーション バイオテクノロジーズ インコーポレイテッド 小胞を調製する方法及びこれから製造される製剤
EP2295543A1 (en) * 2009-09-11 2011-03-16 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Method for the preparation of an influenza virus
US20110110975A1 (en) * 2009-11-06 2011-05-12 Streck, Inc. Inactivated virus compositions and methods of preparing such compositions
AR080972A1 (es) 2010-04-28 2012-05-23 Abbott Biologicals Bv Produccion de componentes virales
US9426989B2 (en) * 2010-05-06 2016-08-30 Novartis Ag Organic peroxide compounds for microorganism inactivation
WO2012006367A2 (en) 2010-07-06 2012-01-12 Variation Biotechnologies, Inc. Compositions and methods for treating influenza
US10736844B2 (en) 2011-01-13 2020-08-11 Variation Biotechnologies Inc. Compositions and methods for treating viral infections
BR112013018074A2 (pt) 2011-01-13 2020-12-01 Variation Biotechnologies, Inc. métodos para a preparação de vesículas e formulações produzidas a partir dessas
EP2667891B1 (en) 2011-01-27 2021-10-06 Gamma Vaccines Pty Limited Combination vaccines
CA2829774C (en) 2011-03-14 2019-09-24 National Research Council Of Canada Method of viral production in cells
US9956281B2 (en) 2011-05-04 2018-05-01 Streck, Inc. Inactivated virus compositions and methods of preparing such compositions
US20140328876A1 (en) 2011-11-18 2014-11-06 Variation Biotechnologies Inc. Synthetic derivatives of mpl and uses thereof
AU2013208693B2 (en) 2012-01-12 2017-12-07 Variation Biotechnologies Inc. Compositions and methods for treating viral infections
EP2806894A4 (en) 2012-01-27 2015-11-04 Variation Biotechnologies Inc METHODS AND COMPOSITIONS FOR THERAPEUTIC AGENTS
WO2019143291A1 (en) * 2018-01-18 2019-07-25 Yisheng Biopharma (Singapore) Pte. Ltd. Method for adapting influenza viruses to vero cells

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2445301A (en) * 1941-12-05 1948-07-13 Univ Pennsylvania Influenza vaccine
BE662899A (no) * 1964-04-22
US4500513A (en) * 1979-05-15 1985-02-19 Miles Laboratories, Inc. Influenza vaccine production in liquid cell culture
CA2205015C (en) * 1994-11-10 2003-04-08 Otfried Kistner Method for producing biologicals in protein-free culture
EP0808361A4 (en) * 1994-11-16 2001-07-18 St Jude Childrens Res Hospital Novel replication process

Also Published As

Publication number Publication date
NO984565D0 (no) 1998-09-30
EP0895535A1 (en) 1999-02-10
US6344354B1 (en) 2002-02-05
EP0895535A4 (en) 2004-09-15
ES2139553T1 (es) 2000-02-16
AU2722997A (en) 1997-10-29
WO1997038094A1 (en) 1997-10-16
CA2250716A1 (en) 1997-10-16
US5824536A (en) 1998-10-20
DE895535T1 (de) 2000-03-02

Similar Documents

Publication Publication Date Title
NO984565L (no) Influensavirus replikert i pattedyrcellekultur og vaksinefremstilling
DE69617583D1 (de) In vitrozellkultur-System
EP1023451A4 (en) METHODS OF REPLICATING VIRUSES IN CULTURES OF MACROPHAGES DERIVED FROM MONOCYTES
FI971955L (fi) Dopamineeristen solujen indusointi in vitro
FI903987A7 (fi) Bioreaktori ja laite eläinsolujen viljelemiseksi
FI953731L (fi) Menetelmä PRRS-viruksen viljelemiseksi ja sen käyttö rokotteissa
DE69734183T8 (de) Sonnenzelle und Herstellungsverfahren
DE59812443D1 (de) Solarzelle und Herstellungsverfahren
DK40591A (da) Tredimensionalt celle- og vaevskultursystem
NO971764D0 (no) Levedyktige, forurensningspartikkelfrie adenoviruser, deres fremstilling og anvendelse
DK1002084T3 (da) Mammalt cytokin: interleukin-B30 og beslægtede reagenser
BR9507678A (pt) Construção de dna vetor de expressão recombinante célula proceso para produzir uma enzima enzima preparação de enzima uso da enzima e cultura
EP0743981A4 (en) HIGH-RESOLUTION CELL CULTURE BIOREACTOR AND ITS USE
FI894998A7 (fi) Soluviljelmämenetelmiä, aineita ja tuotteita
DK0840760T3 (da) Polymerelektrolytter og fremgangsmåde til deres fremstilling
FI20095510L (fi) Suuren solutiheyden bakteerifermentaatioviljelmä
NO993297D0 (no) Fast dyrkningsmedium for mikroorganismer, fremgangsmÕte for fremstilling herav og anvendelse herav
FI963373A7 (fi) Ruumiin ulkopuolinen soluviljelmä ja transplantaatiopakkauksia
DE69928656D1 (de) Gentechnisch hergestellte hefestämme und deren mutanten zur fermentierung von lignocellulosehydrolysate
NO860344L (no) Vevskultur og fremstilling i permeable geler.
FI961848A7 (fi) Parannettu solunviljelymenetelmä ja -väliaine
ZA972887B (en) Influenza virus replicated in mammalian cell culture and vaccine production.
DK489889A (da) Dihydropyridinamider, deres fremstilling og anvendelse i laegemidler
HK1020068A (en) Influenza virus replicated in mammalian cell culture and vaccine production
DK10487A (da) 4-aminoaryldihydropyridinlactoner, deres fremstilling og anvendelse i laegemidler

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application